DFTX Q2 2024 Earnings — Definium Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DFTXDefinium Therapeutics, Inc.

$2B

Q2 2024 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$24M

Net Income

-$6M

EPS (Diluted)

$-0.08

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$268M

Total Liabilities

$66M

Stockholders' Equity

$202M

Cash & Equivalents

$243M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$24M	-$29M	+16.2%
Net Income	-$6M	-$29M	+79.9%